Peptide purity testing: what a 99% result can show

01 · Continued

What does 99% peptide purity mean?: more detail

Testing may also show how much of the expected material is present. It may show which impurities were detected or whether a sample met a stated germ-related requirement.

Those answers are useful, but they are not interchangeable. A result for identity does not prove strength. A purity percentage does not prove sterility. Sterility means the test found no living microorganisms under stated test conditions. A certificate of analysis does not prove that the tested sample is the same material in a vial or that the product is FDA-approved.

One test cannot prove the quality of the whole product or how it was made and handled. Drug quality depends on the full system. This includes product design, controlled manufacturing, checked test methods, written limits, process controls, packaging, stability, and tracking. FDA states that testing alone is not enough because a test usually checks a sample rather than every unit in a batch.

This guide explains how to read testing claims without turning a narrow result into a broad safety or treatment conclusion. It does not provide laboratory procedures, vendor rankings, sourcing advice, or instructions for using a peptide product.

• Identity asks: is this the claimed peptide or material?
• Purity asks: what related and unrelated substances were detected?
• Strength asks: how much active material is present?
• Sterility and endotoxin testing address specific microbiological risks.
• Traceability asks: can the result be connected to this exact lot and container?

02

Start with the exact material.

“Peptide” describes a broad chemical category. It does not identify one molecule, formulation, route, or approved product.

A useful test record should name the exact substance, salt or chemical form where relevant, dosage form, and lot or batch number. It should also name the container and intended status.

An active pharmaceutical ingredient is the active substance in a medicine. It is not the same object as a finished injectable product.

A research-labeled powder, a compounded preparation, and an FDA-approved medicine can share an ingredient name. They can still have different specifications, controls, labels, and evidence.

The first quality question is therefore not “was it tested?” It is “what exactly was tested?” The report should make the test object clear enough to compare with the label and the accompanying records.

If the name is only a nickname, blend, or marketing category, the test may not resolve what the buyer thinks it resolves. FDA’s peptide guidance work highlights the need for identity, impurity, and higher-order structure information.

Higher-order structure means the molecule’s three-dimensional shape.

The guidance also highlights biological-activity information because peptide quality can involve more than a single mass reading.

• Exact peptide name and chemical form
• Drug substance, intermediate, or finished product
• Lot or batch number and container reference
• Labeled strength, dosage form, and route
• Regulatory status stated separately from laboratory results

03

Identity testing asks: is this the claimed substance?

Identity testing is meant to distinguish the claimed substance from other substances. For a peptide, that can involve more than detecting a similar mass.

Closely related sequences, truncated chains, modified forms, salts, aggregates, and degradation products may require methods that can discriminate between them. FDA’s Q6A guidance says an identification test should establish the identity of the drug substance and should discriminate between closely related compounds.

A positive identity result has a narrow meaning: the tested portion showed signals consistent with the named material under the stated method. It does not establish the full impurity profile, biological activity, sterility, stability, or clinical usefulness.

It also does not prove that every container in the lot contains the same material. The strength of the identity conclusion depends on the method, reference standard (known material used for comparison), and laboratory controls. It also depends on the connection between the tested sample and the product being discussed.

• A matching name is not the same as a confirmed identity.
• Mass alone may not resolve sequence, modification, or degradation questions.
• Reference standards and method validation affect confidence.
• Identity does not establish purity, potency, sterility, or approval.

04

Purity is more than one percentage.

A purity result describes how much of the measured signal a method assigned to the intended material. It can also report impurities the method detected. It does not automatically show what share of the sample's total weight is peptide.

Peptide-related impurities can arise during synthesis, purification, handling, or storage. They may include truncated sequences, modified forms, aggregates, residual solvents, degradation products, or other process-related substances.

FDA has noted that peptide impurities can affect safety, effectiveness, and immunogenicity risk, which is the risk of an unwanted immune response. This is why impurity characterization matters.

A report that says “99% pure” is incomplete without the method, calculation basis, named and unnamed impurity limits, and treatment of the remaining material. Different methods can produce different percentages.

A high chromatographic area percentage does not automatically prove the absence of low-level impurities, microbial contamination, endotoxins, or harmful degradation products.

This percentage is the share of signal in one separation test. Purity also does not establish that the material performs as an approved medicine in people.

• Named impurities and unidentified impurities
• Individual and total impurity limits
• Aggregates and degradation products
• Residual solvents or process-related substances
• Method and calculation basis for the reported percentage

05

Strength, assay, and activity answer different questions.

Strength, often reported as assay, addresses the amount of the intended active material in the tested sample. An assay is a test that measures that amount. Strength is not the same as identity or purity.

A sample can contain the named peptide but have less or more active material than the label states. It can also meet an assay result while containing impurities that require separate evaluation.

For a finished product, strength may also involve concentration, content uniformity, delivered volume, or dose uniformity, depending on the dosage form.

Biological activity is another question. Some peptide products require evidence that the material performs the intended function in a qualified biological or functional assay.

A chemical assay can support amount without proving receptor activity or clinical effect. Conversely, a functional signal does not independently confirm sequence, purity, sterility, or exact concentration. FDA’s current peptide product guidance work identifies biological-activity assessment as one part of a larger quality evaluation.

• Identity: what substance is present?
• Assay: how much intended substance is present?
• Purity: what else is present?
• Activity: does the material perform a defined function?
• Clinical benefit: does a treatment help people in a controlled study?

06

Sterility and endotoxins cover different risks.

Sterility is not a guarantee that every unit is sterile forever.

USP explains that sterility cannot be demonstrated by testing every unit because the test is destructive. Sterility assurance therefore depends on linked controls, including facility conditions, validated processes, container closure, handling, and appropriate testing.

FDA’s Q6A guidance states that parenteral products should have sterility and endotoxin requirements. Parenteral products are given by injection or another route that bypasses the digestive tract.

Endotoxins are bacterial components that can cause harmful inflammatory reactions even when living bacteria are not detected. A sterility result does not replace an endotoxin result.

Injectable products may also require controls for visible particles and subvisible particles. Subvisible particles are too small to see without special equipment. Controls may also cover pH, container integrity, and stability. These requirements depend on the exact product and route.

A result from a nonsterile research material cannot be used to establish that an injectable finished product is suitable for people.

• Sterility result and endotoxin result are separate findings.
• Testing is one part of sterility assurance.
• Container closure can affect microbial protection during storage.
• Particulate matter, pH, and stability may also matter for injectables.
• A sterile claim does not establish identity, strength, or clinical safety.

07

How to read a certificate of analysis.

A certificate of analysis, or COA, is a record of reported results against stated specifications. A useful COA should identify the material, lot, test date, method or standard, acceptance limit, and observed result.

It should also identify the laboratory or quality unit and disposition (release or rejection decision).

“Pass” is less informative than the actual result and limit. A result of “not detected” also needs a method and detection limit. Without those details, the report may be difficult to interpret or compare.

A COA is evidence about the tested sample and the reporting system. It is not, by itself, proof of FDA approval, manufacturing quality, clinical benefit, or a complete safety review.

Under 21 CFR 211.84, a manufacturer may use a supplier’s report of analysis only with additional identity testing. It must also have an established process for checking the supplier’s reliability. That rule illustrates the difference between accepting a document and independently establishing confidence in it.

• Material name and exact lot number
• Test method and reference standard
• Acceptance limit and observed result
• Laboratory, quality unit, and report date
• Sample identification and disposition
• Stability or expiry information where relevant

08

Make sure the sample matches the product.

A laboratory result is only as useful as the link between the tested sample and the product in question. The sample record should connect the material to a lot, container, collection date, collector, and receiving record.

Federal good manufacturing practice rules require representative sampling and identification of the material, lot number, source container, date, and person who collected the sample. Those details create traceability. They do not make an unknown sample representative after the fact.

Chain of custody is the documented history of who controlled a sample and when. Breaks can occur when a sample is relabeled, split, stored without a record, or disconnected from the original container.

A genuine-looking PDF can still describe a different lot, a supplier’s retained sample, or a result that cannot be connected to the product offered. A matching lot number helps, but it should be considered with container records, laboratory identity, report integrity, and storage history.

• The report’s lot must match the product’s lot.
• The container or sample identifier should be traceable.
• Collection, receipt, testing, and release records should connect.
• A supplier document is not automatically an independent result.
• A matched sample still does not establish approval or clinical benefit.

09

What testing cannot show.

Testing can reduce uncertainty about defined attributes. It cannot turn an unapproved product into an approved medicine.

It cannot establish that a product is appropriate for a particular person or that a studied product applies to an unrelated formulation. It cannot establish that a research-labeled material has a proven clinical benefit.

It also cannot replace controls that occur during manufacturing, filling, packaging, storage, and distribution.

The defensible conclusion is specific. State what was tested, which method was used, what limit applied, and which lot the result covers. Then state what remains unknown.

If a report does not identify the exact material, lot, method, laboratory, and acceptance criteria, the correct description is “cannot confirm from this document.” Do not call the material “safe” or “pure.” For an approved medicine, the current FDA label and a qualified clinician remain the relevant sources for product-specific use and safety decisions.